Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis
about
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.Antifungal pharmacodynamics: review of the literature and clinical applications.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.Efficacy of micafungin alone or in combination against systemic murine aspergillosis.Recommendations for the treatment of fungal pneumonias.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.New and emerging antifungal agents: impact on respiratory infections.Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adultsAltered Micafungin Pharmacokinetics in Intensive Care Unit PatientsMicafungin: pharmacology, experimental therapeutics and clinical applications.Echinocandin antifungals: review and update.Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosisThe echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Antifungal prophylaxis following reduced-intensity stem cell transplantation.Regulation of expression, activity and localization of fungal chitin synthases.Echinocandins in antifungal pharmacotherapy.In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability.Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders.Pharmacological agents in development for invasive aspergillosis.Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients.Synergistic antifungal activity of KB425796-C in combination with micafungin against Aspergillus fumigatus and its efficacy in murine infection models.New agents for the treatment of systemic fungal infections--current status.Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic.Glucan Synthase Inhibitors
P2860
Q33722115-2951DC15-053F-47A0-8863-A4E6C4D5110BQ33938201-F7558525-C073-465C-A984-F17E1CB94F71Q33980368-0E2BA5BC-094B-4DA0-B6F1-1493DC52F645Q33983499-F88C0604-352E-4302-9541-2E9B1AAB7597Q33983506-697EE681-C870-4461-A57B-70FA233DF3B7Q33983618-F5014252-517C-4B6A-BA4F-EC0F8E549639Q34083129-9F9D5EDC-6535-4EB9-9773-D09168406A74Q34108880-D9F8E7DE-874B-4186-861C-8ADE6EBF15F3Q34884594-3D43E1E9-9513-4263-9610-43A89B5ABC99Q35183728-1F270033-8C58-4E0C-8ED7-224899E71965Q35185757-689918DD-33B3-46D6-B80E-D3EDD7D3A5E9Q35627629-CCCEF5D6-7188-4E10-91B7-C8A9C99B2D0DQ35635928-656D51E1-FC3F-4188-A29D-37C91401CED5Q35860004-B1F4DB18-961B-47C3-AF2B-D59E11BF79E7Q36120798-88374B88-D2BB-4445-A6DC-4FEC49CAB1D6Q36441524-E4658D76-7D2E-4BD2-B5A4-DA7A8794899EQ36593863-2C83930A-37C1-40A7-8875-4EF61C103326Q36626518-B00BA270-A02E-4133-AF83-3AB54EC8CF7FQ36658236-1777FD61-ECE9-4807-A9D4-CD89F5453F17Q37869907-F27F1E42-1338-4203-88B5-FD0399836C1BQ39458862-04A9388C-793D-4275-BCDE-121670ACDF00Q39743508-563EA8F1-1C81-43EA-A44D-569635BE131EQ39755556-0EFFF9B8-046B-4FAF-8569-E6830CCB8D3EQ40313049-F70FF2B5-2539-4CB9-A595-84A8E148D7A2Q40409386-2963A78B-95F1-4C9A-B218-DAA3307DF3ACQ40667866-EAFFECB0-0FBB-42E3-AF3D-F601836D50E2Q42163324-570E0BC4-7E9E-453C-A2A5-B1E422438F08Q42710747-9FE4EF05-224C-4BCF-97C0-5F45EC401252Q46576615-99B43E35-7D7B-45AA-960D-A3284BC96A08Q46707135-06684708-E9D5-44E1-B785-A2877B0D5985Q58033533-85303C6C-1EA3-4A4C-8960-80BF023843DF
P2860
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@ast
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@en
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@nl
type
label
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@ast
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@en
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@nl
prefLabel
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@ast
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@en
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@nl
P2093
P2860
P1476
Efficacy of FK463, a new lipop ...... els of pulmonary aspergillosis
@en
P2093
F Matsumoto
S Kuwahara
S Matsumoto
T Ushitani
P2860
P304
P356
10.1128/AAC.44.3.619-621.2000
P407
P577
2000-03-01T00:00:00Z